Featured Research

from universities, journals, and other organizations

New Non-aspirin Pain Drug Proves Effective Against Recurrent Prostate Cancer

Date:
June 10, 2004
Source:
University Of North Carolina School Of Medicine
Summary:
Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

CHAPEL HILL -- Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

The new findings demonstrate that Cox-2 inhibitors may have anti-tumor effects on prostate cancer and may slow disease progression in men whose PSA blood tests indicate the cancer's recurrence, the researchers said. Findings were presented June 6 at the American Society of Clinical Oncology's annual meeting.

Currently, no effective treatment options exist for the estimated 50,000 men who annually develop the first signs of cancer recurrence - called biochemical relapse, a detectable and rising PSA level after surgery or radiation therapy for prostate cancer. For these otherwise healthy individuals, the first clinical signs of cancer relapse may be years ahead.

"If the PSA test points to a recurrence, the good news is it gives us a lead time of up to seven years. The bad news is we don't have anything appropriate and effective to offer at this early stage of recurrence," said Dr. Raj S. Pruthi, the study's principal investigator. "The use of chemotherapy in prostate cancer has been typically disappointing in these patients when viewed in terms of efficacy and toxicity."

Pruthi, assistant professor of surgery-urology at the School of Medicine, also co-directs the Multidisciplinary Program for Urologic Oncology at the UNC Lineberger Comprehensive Cancer Center. The findings were based on 24 prostate cancer patients in biochemical relapse who were treated with a Cox-2 inhibitor and followed for more than one year. After three months, 22 of 24 patients (92 percent) showed a significant inhibitory effect on their PSA levels, including 11 patients whose PSA either declined or stabilized. For the remaining 13 patients, 11 had a dramatic slowing of their PSA doubling time, or rate of PSA increase, and two patients showed no initial change.

"Still, their rate of PSA increase slowed during their 12-month follow-up," Pruthi said.

Halting the disease through hormonal therapy aimed at shutting down male sex hormones has not been shown to influence disease progression or survival in this group of patients, Pruthi said. Moreover, it may unnecessarily expose symptom-free patients to the therapy's side effects, he added.

"The vast majority of patients are simply watched expectantly until they develop clinical symptoms of disease or metastatic disease (i.e. spread around the body), at which time we begin hormonal therapy," he said. "Therapeutic alternatives that are simple, non-toxic and efficacious clearly need to be identified."

Cox-2 inhibitors may represent the needed alternative, Pruthi said, considering that the cellular enzyme cyclooxygenase (Cox-2) has been implicated in the development and growth of some cancers, including colon, breast, bladder and prostate malignancies.

While the precise molecular mechanisms for Cox-2's effect on tumor growth remain unclear, increased gene expression of Cox-2 in tumor cells has been linked with decreased programmed cell death, increased tumor invasiveness, suppressed immune function and angiogenesis, or blood vessel growth.

In the laboratory, Cox-2 inhibitors have been shown to have anti-tumor activities in human colon, breast, lung and prostate cancer tissues. "Recent evidence has shown that Cox-2 is over-expressed in human prostate cancer tissue and that Cox-2 inhibition has potent anti-tumor activity both in vitro and in vivo," Pruthi said.

Late in the 1980s and 1990s, some evidence from epidemiologic studies had suggested that people who take non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief have a reduced risk of colon cancer, and more recent studies have suggested that this reduced risk may be true for prostate cancer, as well.

These drugs, which include aspirin, block Cox-2, which is produced in response to injury and enhances the inflammatory response, resulting in pain, inflammation and swelling. But NSAIDs also block expression of Cox-1, which is produced constantly and helps preserve the stomach's lining. Hence the increased risk of gastrointestinal side effects associated with taking NSAIDs.

The advent in 1998 of celecoxib, first of the two cyclooxygenase-2 specific (Cox-2) inhibitor drugs approved by the U.S. Food and Drug Administration, provided the same effectiveness against pain and swelling of inflammation as the older NSAIDs but without the increased gastrointestinal risk, including stomach ulcers. These drugs are sold in the United States under the brand names Celebrex and Vioxx.

In a clinical study, people at hereditarily high risk for developing pre-cancerous colon polyps were given celecoxib. They showed a decrease in the number of these polyps. Consequently, the FDA has approved the use of celecoxib for the prevention of pre-cancerous polyps in these patients.

"We think Cox-2 inhibitors may help delay or prevent disease progression in men with recurrent prostate cancer after definitive radiation therapy or surgery and thereby help extend the time until hormonal therapy is needed," Pruthi said.

"This clinical trial will better evaluate the clinical potential of Cox-2 as an anti-tumor medication in prostate cancer," he added. "We're interested in determining if this group of medications work for patients who otherwise are told 'Your cancer has come back but we have no appropriate treatment options for you at this stage.' "

Up to 100 patients will be studied in this UNC investigation. Support for the research comes from the Lineberger Center.


Story Source:

The above story is based on materials provided by University Of North Carolina School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina School Of Medicine. "New Non-aspirin Pain Drug Proves Effective Against Recurrent Prostate Cancer." ScienceDaily. ScienceDaily, 10 June 2004. <www.sciencedaily.com/releases/2004/06/040610074916.htm>.
University Of North Carolina School Of Medicine. (2004, June 10). New Non-aspirin Pain Drug Proves Effective Against Recurrent Prostate Cancer. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2004/06/040610074916.htm
University Of North Carolina School Of Medicine. "New Non-aspirin Pain Drug Proves Effective Against Recurrent Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/06/040610074916.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins